Deutsch English Français

Contact

EP4132530

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP4132530

EP4132530 - CO-TREATMENT WITH CDK4/6 AND CDK2 INHIBITORS TO SUPPRESS TUMOR ADAPTATION TO CDK2 INHIBITORS [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 06.10.2023 Database last updated on 26.07.2024
Former	Request for examination was made Status updated on 13.01.2023
Former	The international publication has been made Status updated on 16.10.2021
Former	unknown Status updated on 26.04.2021
Most recent event Tooltip	06.10.2023	Application deemed to be withdrawn	published on 08.11.2023 [2023/45]
Applicant(s)	For all designated states Pfizer Inc. 66 Hudson Boulevard East New York, NY 10001-2192 / US
	For all designated states The Regents of the University of Colorado, a body corporate 1800 Grant Street, 8th Floor Denver, CO 80203 / US
	[2023/19]
Former [2023/07]	For all designated states Pfizer Inc. 235 East 42nd Street New York, NY 10017 / US
	For all designated states The Regents of the University of Colorado, a body corporate 1800 Grant Street, 8th Floor Denver, CO 80203 / US
Inventor(s)	01 / ARORA, Mansi 100 Roundtop Rd. Framingham, Massachusetts 01701 / US
	02 / DANN, Stephen George 17124 Saint Andrews Drive Poway, California 92064 / US
	03 / GOODMAN MILLER, Nicole Lee 14129 Los Neitos Avenue Poway, California 92064 / US
	04 / SPENCER, Sabrina 1836 22nd Street Boulder, Colorado 80302 / US
	05 / VANARSDALE, Todd Lee c/o Pfizer Inc. 10777 Science Center Drive San Diego, California 92121 / US
	[2023/07]
Representative(s)	Berggren Oy P.O. Box 16 Eteläinen Rautatiekatu 10A 00101 Helsinki / FI
	[2023/07]
Application number, filing date	21719267.3	07.04.2021
	[2023/07]
	WO2021IB52894
Priority number, date	US202063007329P	08.04.2020 Original published format: US 202063007329 P
	US202163165049P	23.03.2021 Original published format: US 202163165049 P
	[2023/07]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2021205363
	Date:	14.10.2021
	Language:	EN
	[2021/41]
	Type:	A1 Application with search report
	No.:	EP4132530
	Date:	15.02.2023
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 14.10.2021 takes the place of the publication of the European patent application.
	[2023/07]
Search report(s)	International search report - published on:	EP	14.10.2021
Classification	IPC:	A61K31/506, A61K31/519, A61K45/06, A61P35/00	[2023/07]
	CPC:	A61K45/06 (EP); A61K31/519 (EP,US); A61K31/506 (EP,US); A61P35/00 (EP,US)
	C-Set:	A61K31/506, A61K2300/00 (EP); A61K31/519, A61K2300/00 (EP)
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/07]
Title	German:	CO-BEHANDLUNG MIT CDK4/6- UND CDK2-INHIBITOREN ZUR UNTERDRÜCKUNG DER TUMORANPASSUNG AN CDK2-INHIBITOREN	[2023/07]
	English:	CO-TREATMENT WITH CDK4/6 AND CDK2 INHIBITORS TO SUPPRESS TUMOR ADAPTATION TO CDK2 INHIBITORS	[2023/07]
	French:	CO-TRAITEMENT AVEC DES INHIBITEURS DE CDK4/6 ET DE CDK2 POUR SUPPRIMER L'ADAPTATION TUMORALE À DES INHIBITEURS DE CDK2	[2023/07]
Entry into regional phase	11.10.2022	National basic fee paid
	11.10.2022	Designation fee(s) paid
	11.10.2022	Examination fee paid
Examination procedure	11.10.2022	Examination requested [2023/07]
	11.10.2022	Date on which the examining division has become responsible
	26.05.2023	Application deemed to be withdrawn, date of legal effect [2023/45]
	21.06.2023	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time [2023/45]
	21.06.2023	Despatch of communication of loss of particular rights: Claims {1}
Fees paid	Renewal fee
	21.03.2023	Renewal fee patent year 03
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited in	International search	[X]WO2017147326 (UNIV NEW YORK STATE RES FOUND [US]) [X] 1-4,6,8-12,14,16 * page 1, line 5 - line 9 * * page 2, line 14 - line 29 * * page 11, line 4 - line 6; example 2; table 2 * * claims 1-9,12 * * page 23, line 1 - page 24, line 3 *;
		[X]WO2017198685 (UNIVERSITÉ LIBRE DE BRUXELLES [BE]) [X] 1-4,6,8-12,14,16 * abstract * * page 58, line 20 - line 32; figure 5; claim - *;
		[X]US2019134044 (SHAILUBHAI KUNWAR [US]) [X] 1-6,8-14,16 * paragraphs [0003] - [0004] * * paragraphs [0009] , [0027] , [0028] * * paragraphs [0240] , [0242]; figures 8,19,50; examples 1,2 * * claims 1,2,21,22 *;
		[XP]WO2020168178 (INCYTE CORP [US], et al) [XP] 1-16 * page 2, line 13 - line 33 * * page 32, line 16 - page 35, line 6 * * page 91, lines 3-8 - lines 30-31 ** page 95, lines 33-34 *;
		[X] - Hall Claire R ET AL, "DEVELOPMENT OF CDK2 INHIBITORS TO OVERCOME PRIMARY AND ACQUIRED RESISTANCE TO CDK4/6 INHIBITION", 2019 AACR Annual Meeting, March 30 -April 3, 2019 , Atlanta, GA, (20190401), URL: https://www.g1therapeutics.com/file.cfm/34/docs/ot-G1_AACR2019_Hall.pdf, (20210602), XP055810171 [X] 1-16 * the whole document *
		[XD] - C. E. CALDON ET AL, "Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells", MOLECULAR CANCER THERAPEUTICS, US, (20120507), vol. 11, no. 7, doi:10.1158/1535-7163.MCT-11-0963, ISSN 1535-7163, pages 1488 - 1499, XP055692618 [XD] 1-16 * abstract * * page 1494, column l, paragraph l - page 1496, column l, paragraph 1; figures 5,6B * * page 1498, column l, paragraph 2 * DOI: http://dx.doi.org/10.1158/1535-7163.MCT-11-0963
		[X] - Litchfield Lacey Et Al., "Combinations with CDK4/6 inhibitors to treat cancers with mutations in both KRAS and CDKN2A \| Molecular Cancer Research", (20181201), URL: https://mcr.aacrjournals.org/content/18/5_Supplement/PR06, (20210604), XP055810458 [X] 1-4,6,9-12,14 * the whole document *
		[X] - Ce Mills Et Al., "Omics profiling of CDK4/6 inhibitors reveals functionally important secondary targets of abemaciclib", Cancer Research, (20190201), URL: https://cancerres.aacrjournals.org/content/79/4_Supplement/PD1-12, (20210602), XP055810164 [X] 1-4,6,9-12,14 * the whole document *
		[XP] - PANDEY KAMAL ET AL, "Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence", CANCERS, vol. 12, no. 12, doi:10.3390/cancers12123566, (20201129), page 3566, URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768442/pdf/cancers-12-03566.pdf, XP055810147 [XP] 1-16 * the whole document * DOI: http://dx.doi.org/10.3390/cancers12123566
	by applicant	WO9111172
		WO9402518
		WO9855148
		WO0035298
		US6106864
		US6936612
		US8598197
		US8598186
		US8691830
		US8822683
		US8829102
		US9102682
		US9260442
		US9481591
		US9499564
		US10233188
		USRE47739E
		- CAS, no. 2412559-19-2
		- CAS , no. 872573-93-8
		- OHTANI, K.DEGREGORI, J.NEVINS, J.R., "Regulation of the cyclin E gene by transcription factor E2F1.", Proc Natl Acad Sci U S A, (19950000), vol. 92, doi:10.1073/pnas.92.26.12146, pages 12146 - 12150, XP002138279 DOI: http://dx.doi.org/10.1073/pnas.92.26.12146
		- LIANGCHEN, Expert Opinion in Therapeutic Patents, (20010000), vol. 11, no. 6, pages 981 - 986
		- H. LIEBERMANL. LACHMAN, Pharmaceutical Dosage Forms: Tablets, Marcel Dekker, (19800000), vol. 1
		- VERMA et al., Pharmaceutical Technology On-line, (20010000), vol. 25, no. 2, pages 1 - 14
		- FINNINMORGAN, J Pharm Sci, (19991000), vol. 88, no. 10, pages 955 - 958
		- T HIGUCHIW STELLA, "Pro-drugs as Novel Delivery Systems", ACS Symposium Series, vol. 14
		- AKIYAMA, T.OHUCHI, T.SUMIDA, S.MATSUMOTO, K.TOYOSHIMA, K., "Phosphorylation of the retinoblastoma protein by cdk2.", Proc Natl Acad Sci U S A, (19920000), vol. 89, pages 7900 - 7904
		- AKTAS, H.CAI, H.COOPER, G.M., "Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D 1 and the Cdk inhibitor p27KIP 1.", Mol Cell Biol, (19970000), vol. 10, no. 17, pages 3850 - 3857
		- ALEEM, E.KIYOKAWA, H.KALDIS, P., "Cdc2-cyclin E complexes regulate the Gl/S phase transition.", Nat Cell Biol, (20050000), vol. 7, pages 831 - 836
		- ARORA, M.MOSER, J.PHADKE, H.BASHA, A.A.SPENCER, S.L., "Endogenous Replication Stress in Mother Cells Leads to Quiescence of Daughter Cells", Cell reports, (20170000), vol. 19, no. 15, pages 1351 - 1364
		- BALDIN, V.LUKAS, J.MARCOTE, M.J.PAGANO, M.DRAETTA, G., "Cyclin D1 is a nuclear protein required for cell cycle progression in Gl.", Genes Dev, (19930000), vol. 7, pages 812 - 821, XP008032844
		- BARRIERE, C.SANTAMARIA, D.CERQUEIRA, A.GALAN, J.MARTIN, A.ORTEGA, S.MALUMBRES, M.DUBUS, P.BARBACID, M., "Mice thrive without Cdk4 and Cdk2.", Mol Oncol, (20070000), vol. 1, pages 72 - 83
		- BERTHET, C.ALEEM, E.COPPOLA, V.TESSAROLLO, L.KALDIS, P., "Cdk2 knockout mice are viable.", Curr Biol, (20030000), vol. 13, doi:10.1016/j.cub.2003.09.024, pages 1775 - 1785, XP004576535 DOI: http://dx.doi.org/10.1016/j.cub.2003.09.024
		- BROOKES, S.GAGRICA, S.SANIJ, E.ROWE, J.GREGORY, F.J.HARA, E.PETERS, G., "Evidence for a CDK4-dependent checkpoint in a conditional model of cellular senescence.", Cell Cycle, (20150000), vol. 14, pages 1164 - 1173
		- BURKHART, D.L.SAGE, J., "Cellular mechanisms of tumour suppression by the retinoblastoma gene.", Nat Rev Cancer, (20080000), vol. 8, pages 671 - 682
		- CALDON, C.E.SERGIO, C.M.KANG, J.MUTHUKARUPPAN, A.BOERSMA, M.N.STONE, A.BARRACLOUGH, J.LEE, C.S.BLACK, M.A.MILLER, L.D. et al., "Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells.", Mol Cancer Ther, (20120000), vol. 11, doi:10.1158/1535-7163.MCT-11-0963, pages 1488 - 1499, XP055692618 DOI: http://dx.doi.org/10.1158/1535-7163.MCT-11-0963
		- CAPPELL, S.D.CHUNG, M.JAIMOVICH, A.SPENCER, S.L.MEYER, T., "Irreversible APC(Cdhl) Inactivation Underlies the Point of No Return for Cell-Cycle Entry.", Cell, (20160000), vol. 166, pages 167 - 180
		- CHELLAPPAN, S.P.HIEBERT, S.MUDRYJ, M.HOROWITZ, J.M.NEVINS, J.R., "The E2F transcription factor is a cellular target for the RB protein.", Cell, (19910000), vol. 65, doi:10.1016/0092-8674(91)90557-F, pages 1053 - 1061, XP023908721 DOI: http://dx.doi.org/10.1016/0092-8674(91)90557-F
		- DESHPANDE, A.SICINSKI, P.HINDS, P.W., "Cyclins and cdks in development and cancer: a perspective.", Oncogene, (20050000), vol. 24, pages 2909 - 2915
		- EDWARDS, A.HAAS, W., "Multiplexed Quantitative Proteomics for High-Throughput Comprehensive Proteome Comparisons of Human Cell Lines", Methods in molecular biology, (20160000), vol. 1394, pages 1 - 13
		- EVRON, E.UMBRICHT, C.B.KORZ, D.RAMAN, V.LOEB, D.M.NIRANJAN, B.BULUWELA, L.WEITZMAN, S.A.MARKS, J.SUKUMAR, S., "Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation.", Cancer Res, (20010000), vol. 61, pages 2782 - 2787, XP008124596
		- FISK, H.A.WINEY, M., "The mouse Mpslp-like kinase regulates centrosome duplication.", Cell, (20010000), vol. 106, pages 95 - 104
		- FRANCO, J.WITKIEWICZ, A.K.KNUDSEN, E.S., "CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.", Oncotarget, (20140000), vol. 5, doi:10.18632/oncotarget.2270, pages 6512 - 6525, XP055275078 DOI: http://dx.doi.org/10.18632/oncotarget.2270
		- GABRIELLI, B.G.SARCEVIC, B.SINNAMON, J.WALKER, G.CASTELLANO, M.WANG, X.Q.ELLEM, K.A., "A cyclin D-Cdk4 activity required for G2 phase cell cycle progression is inhibited in ultraviolet radiation-induced G2 phase delay.", J Biol Chem, (19990000), vol. 274, pages 13961 - 13969
		- GRIM, J.E.CLURMAN, B.E., "Cycling without CDK2?", Trends Cell Biol, (20030000), vol. 13, pages 396 - 399
		- GUERRA, C.MIJIMOLLE, N.DHAWAHIR, A.DUBUS, P.BARRADAS, M.SERRANO, M.CAMPUZANO, V.BARBACID, M., "Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context.", Cancer Cell, (20030000), vol. 4, pages 111 - 120
		- HATA, A.N.NIEDERST, M.J.ARCHIBALD, H.L.GOMEZ-CARABALLO, M.SIDDIQUI, F.M.MULVEY, H.E.MARUVKA, Y.E.JI, F.BHANG, H.E.KRISHNAMURTHY RADHAKRISHNA, V. et al., "Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition.", Nature medicine, (20160000), vol. 22, pages 262 - 269
		- HERRERA-ABREU, M.T.PALAFOX, M.ASGHAR, U.RIVAS, M.A.CUTTS, R.J.GARCIA-MURILLAS, I.PEARSON, A.GUZMAN, M.RODRIGUEZ, O.GRUESO, J. et al., "Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.", Cancer Res, (20160000), vol. 76, doi:10.1158/0008-5472.CAN-15-0728, pages 2301 - 2313, XP055506969 DOI: http://dx.doi.org/10.1158/0008-5472.CAN-15-0728
		- HU, M.G.DESHPANDE, A.ENOS, M.MAO, D.HINDS, E.A.HU, G.F.CHANG, R.GUO, Z.DOSE, M.MAO, C. et al., "A requirement for cyclin-dependent kinase 6 in thymocyte development and tumorigenesis.", Cancer Res, (20090000), vol. 69, pages 810 - 818
		- HUTTLIN, E.L.JEDRYCHOWSKI, M.P.ELIAS, J.E.GOSWAMI, T.RAD, R.BEAUSOLEIL, S.A.VILLEN, J.HAAS, W.SOWA, M.E.GYGI, S.P., "A tissue-specific atlas of mouse protein phosphorylation and expression.", Cell, (20100000), vol. 143, doi:10.1016/j.cell.2010.12.001, pages 1174 - 1189, XP028362278 DOI: http://dx.doi.org/10.1016/j.cell.2010.12.001
		- JONKERS, J.MEUWISSEN, R.VAN DER GULDEN, H.PETERSE, H.VAN DER VALK, M.BERNS, A., "Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer.", Nat Genet, (20010000), vol. 29, pages 418 - 425
		- KATO, J.MATSUSHIME, H.HIEBERT, S.W.EWEN, M.E.SHERR, C.J., "Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4.", Genes Dev, (19930000), vol. 7, pages 331 - 342, XP000783943
		- KATSUNO, Y.SUZUKI, A.SUGIMURA, K.OKUMURA, K.ZINELDEEN, D.H.SHIMADA, M.NIIDA, H.MIZUNO, T.HANAOKA, F.NAKANISHI, M., "Cyclin A-Cdkl regulates the origin firing program in mammalian cells.", Proc Natl Acad Sci USA, (20090000), vol. 106, pages 3184 - 3189
		- KEYOMARSI, K.TUCKER, S.L.BUCHHOLZ, T.A.CALLISTER, M.DING, Y.HORTOBAGYI, G.N.BEDROSIAN, I.KNICKERBOCKER, C.TOYOFUKU, W.LOWE, M. et al., "Cyclin E and survival in patients with breast cancer.", N Engl J Med, (20020000), vol. 347, pages 1566 - 1575
		- KHATIB, Z.A.MATSUSHIME, H.VALENTINE, M.SHAPIRO, D.N.SHERR, C.J.LOOK, A.T., "Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas.", Cancer Res, (19930000), vol. 53, pages 5535 - 5541
		- LAPEK, J.D., JR.GRENINGER, P.MORRIS, R.AMZALLAG, A.PRUTEANU-MALINICI, I.BENES, C.H.HAAS, W., "Detection of dysregulated protein-association networks by high-throughput proteomics predicts cancer vulnerabilities.", Nature biotechnology, (20170000), vol. 35, pages 983 - 989
		- LAPEK, J.D., JR.LEWINSKI, M.K.WOZNIAK, J.M.GUATELLI, J.GONZALEZ, D.J., "Quantitative Temporal Viromics of an Inducible HIV-1 Model Yields Insight to Global Host Targets and Phospho-Dynamics Associated with Protein Vpr", Molecular & cellular proteomics : MCP, (20170000), vol. 16, pages 1447 - 1461
		- LEE, C.L.MODING, E.J.HUANG, X.LI, Y.WOODLIEF, L.Z.RODRIGUES, R.C.MA, Y.KIRSCH, D.G., "Generation of primary tumors with Flp recombinase in FRT-flanked p53 mice.", Dis Model Mech, (20120000), vol. 5, pages 397 - 402
		- LINDQVIST, A.RODRIGUEZ-BRAVO, V.MEDEMA, R.H., "The decision to enter mitosis: feedback and redundancy in the mitotic entry network.", Journal of Cell Biology, (20090000), vol. 185, pages 193 - 202
		- LOHKA, M.J.HAYES, M.K.MALLER, J.L., "Purification of maturation-promoting factor, an intracellular regulator of early mitotic events.", Proc Natl Acad Sci U S A, (19880000), vol. 85, pages 3009 - 3013
		- LUNDBERG, A.S.WEINBERG, R.A., "Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes.", Molecular and cellular biology, (19980000), vol. 18, pages 753 - 761
		- MALUMBRES, M.SOTILLO, R.SANTAMARIA, D.GALAN, J.CEREZO, A.ORTEGA, S.DUBUS, P.BARBACID, M., "Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6.", Cell, (20040000), vol. 118, pages 493 - 504
		- MASSAGUE, J., "G1 cell-cycle control and cancer.", Nature, (20040000), vol. 432, pages 298 - 306
		- MATSUSHIME, H.EWEN, M.E.STROM, D.K.KATO, J.Y.HANKS, S.K.ROUSSEL, M.F.SHERR, C.J., "Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins.", Cell, (19920000), vol. 71, doi:10.1016/0092-8674(92)90360-O, pages 323 - 334, XP026024972 DOI: http://dx.doi.org/10.1016/0092-8674(92)90360-O
		- MATSUSHIME, H.QUELLE, D.E.SHURTLEFF, S.A.SHIBUYA, M.SHERR, C.J.KATO, J.Y., "D-type cyclin-dependent kinase activity in mammalian cells.", Mol Cell Biol, (19940000), vol. 14, doi:10.1128/MCB.14.3.2066, pages 2066 - 2076, XP055090925 DOI: http://dx.doi.org/10.1128/MCB.14.3.2066
	- MERRICK, K.A.WOHLBOLD, L.ZHANG, C.ALLEN, J.J.HORIUCHI, D.HUSKEY, N.E.GOGA, A.SHOKAT, K.M.FISHER, R.P., "Switching Cdk2 On or Off with Small Molecules to Reveal Requirements in Human Cell Proliferation", Molecular Cell, (20110000), vol. 42, pages 624 - 636
	- MEYERSON, M.HARLOW, E., "Identification of G1 kinase activity for cdk6, a novel cyclin D partner.", Mol Cell Biol, (19940000), vol. 14, pages 2077 - 2086
	- MITTNACHT, S.LEES, J.A.DESAI, D.HARLOW, E.MORGAN, D.O.WEINBERG, R.A., "Distinct sub-populations of the retinoblastoma protein show a distinct pattern of phosphorylation.", EMBO J, (19940000), vol. 13, pages 118 - 127
	- MOONS, D.S.JIRAWATNOTAI, S.PARLOW, A.F.GIBORI, G.KINEMAN, R.D.KIYOKAWA, H., "Pituitary hypoplasia and lactotroph dysfunction in mice deficient for cyclin-dependent kinase-4.", Endocrinology, (20020000), vol. 143, pages 3001 - 3008
	- MUSGROVE, E.A.CALDON, C.E.BARRACLOUGH, J.STONE, A.SUTHERLAND, R.L., "Cyclin D as a therapeutic target in cancer.", Nat Rev Cancer, (20110000), vol. 11, pages 558 - 572
	- NARASIMHA, A.M.KAULICH, M.SHAPIRO, G.S.CHOI, Y.J.SICINSKI, P.DOWDY, S.F., "Cyclin D activates the Rb tumor suppressor by mono-phosphorylation", Elife, (20140000), vol. 3
	- OKUDA, M.HORN, H.F.TARAPORE, P.TOKUYAMA, Y.SMULIAN, A.G.CHAN, P.K.KNUDSEN, E.S.HOFINANN, I.A.SNYDER, J.D.BOVE, K.E. et al., "Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication.", Cell, (20000000), vol. 103, doi:10.1016/S0092-8674(00)00093-3, pages 127 - 140, XP002266900 DOI: http://dx.doi.org/10.1016/S0092-8674(00)00093-3
	- ORTEGA, S.PRIETO, I.ODAJIMA, J.MARTIN, A.DUBUS, P.SOTILLO, R.BARBERO, J.L.MALUMBRES, M.BARBACID, M., "Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice.", Nat Genet, (20030000), vol. 35, doi:10.1038/ng1232, pages 25 - 31, XP002378428 DOI: http://dx.doi.org/10.1038/ng1232
	- PARK, S.LEE, J.DO, I.G.JANG, J.RHO, K.AHN, S.MARUJA, L.KIM, S.J.KIM, K.M.MAO, M. et al., "Aberrant CDK4 amplification in refractory rhabdomyosarcoma as identified by genomic profiling.", Sci Rep, (20140000), vol. 4, page 3623
	- PETERSEN, B.O.LUKAS, J.SORENSEN, C.S.BARTEK, J.HELIN, K., "Phosphorylation of mammalian CDC6 by cyclin A/CDK2 regulates its subcellular localization.", EMBO J, (19990000), vol. 18, pages 396 - 410
	- RAMIREZ, M.RAJARAM, S.STEININGER, R.J.OSIPCHUK, D.ROTH, M.A.MORINISHI, L.S.EVANS, L.JI, W.HSU, C.H.THURLEY, K. et al., "Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells.", Nature communications, (20160000), vol. 7, page 10690
	- RANE, S.G.DUBUS, P.METTUS, R.V.GALBREATH, E.J.BODEN, G.REDDY, E.P.BARBACID, M., "Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia.", Nat Genet, (19990000), vol. 22, pages 44 - 52
	- SAHA, P.CHEN, J.THOME, K.C.LAWLIS, S.J.HOU, Z.H.HENDRICKS, M.PARVIN, J.D.DUTTA, A., "Human CDC6/Cdcl8 associates with Orcl and cyclin-cdk and is selectively eliminated from the nucleus at the onset of S phase.", Mol Cell Biol, (19980000), vol. 18, pages 2758 - 2767, XP000886479
	- SANIDAS, I.MORRIS, R.FELLA, K.A.RUMDE, P.H.BOUKHALI, M.TAI, E.C.TING, D.T.LAWRENCE, M.S.HAAS, W.DYSON, N.J., "A Code of Mono-phosphorylation Modulates the Function of RB.", Mol Cell, (20190000), vol. 73, pages 985 - 1000
	- SANTAMARIA, D.BARRIERE, C.CERQUEIRA, A.HUNT, S.TARDY, C.NEWTON, K.CACERES, J.F.DUBUS, P.MALUMBRES, M.BARBACID, M., "Cdkl is sufficient to drive the mammalian cell cycle.", Nature, (20070000), vol. 448, pages 811 - 815
	- SARCEVIC, B.LILISCHKIS, R.SUTHERLAND, R.L., "Differential phosphorylation of T-47D human breast cancer cell substrates by Dl-, D3-, E-, and A-type cyclin-CDK complexes.", J Biol Chem, (19970000), vol. 272, pages 33327 - 33337
	- SCHWARZ, C.JOHNSON, A.KOIVOMAGI, M.ZATULOVSKIY, E.KRAVITZ, C.J.DONCIC, A.SKOTHEIM, J.M., "A Precise Cdk Activity Threshold Determines Passage through the Restriction Point.", Mol Cell, (20180000), vol. 69, pages 253 - 264
	- SHAFFER, S.M.DUNAGIN, M.C.TORBORG, S.R.TORRE, E.A.EMERT, B.KREPLER, C.BEQIRI, M.SPROESSER, K.BRAFFORD, P.A.XIAO, M. et al., "Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance.", Nature, (20170000), vol. 546, pages 431 - 435
	- SHARMA, S.V.LEE, D.Y.LI, B.QUINLAN, M.P.TAKAHASHI, F.MAHESWARAN, S.MCDERMOTT, U.AZIZIAN, N.ZOU, L.FISCHBACH, M.A. et al., "A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations.", Cell, (20100000), vol. 141, doi:10.1016/j.cell.2010.02.027, pages 69 - 80, XP002718050 DOI: http://dx.doi.org/10.1016/j.cell.2010.02.027
	- SHERR, C.J., "Mammalian G1 cyclins.", Cell, (19930000), vol. 73, doi:10.1016/0092-8674(93)90636-5, pages 1059 - 1065, XP023908514 DOI: http://dx.doi.org/10.1016/0092-8674(93)90636-5
	- SHERR, C.J., "G1 phase progression: cycling on cue.", Cell, (19940000), vol. 79, doi:10.1016/0092-8674(94)90540-1, pages 551 - 555, XP023908682 DOI: http://dx.doi.org/10.1016/0092-8674(94)90540-1
	- SHERR, C.J.ROBERTS, J.M., "Living with or without cyclins and cyclin-dependent kinases.", Genes Dev, (20040000), vol. 18, pages 2699 - 2711
	- SPENCER, S.L.CAPPELL, S.D.TSAI, F.C.OVERTON, K.W.WANG, C.L.MEYER, T., "The proliferation-quiescence decision is controlled by a bifurcation in CDK2 activity at mitotic exit.", Cell, (20130000), vol. 155, doi:10.1016/j.cell.2013.08.062, pages 369 - 383, XP028737314 DOI: http://dx.doi.org/10.1016/j.cell.2013.08.062
	- TETSU, O.MCCORMICK, F., "Proliferation of cancer cells despite CDK2 inhibition.", Cancer Cell, (20030000), vol. 3, doi:10.1016/S1535-6108(03)00053-9, pages 233 - 245, XP002498332 DOI: http://dx.doi.org/10.1016/S1535-6108(03)00053-9
	- WOHLBOLD, L.MERRICK, K.A.DE, S.AMAT, R.KIM, J.H.LAROCHELLE, S.ALLEN, J.J.ZHANG, C.SHOKAT, K.M.PETRINI, J.H. et al., "Chemical genetics reveals a specific requirement for Cdk2 activity in the DNA damage response and identifies Nbsl as a Cdk2 substrate in human cells.", PLoS Genet, (20120000), vol. 8, page el002935
	- XU, T.PARK, S.K.VENABLE, J.D.WOHLSCHLEGEL, J.A.DIEDRICH, J.K.COCIORVA, D.LU, B.LIAO, L.HEWEL, J.HAN, X. et al., "ProLuCID: An improved SEQUEST-like algorithm with enhanced sensitivity and specificity.", Journal of proteomics, (20150000), vol. 129, doi:10.1016/j.jprot.2015.07.001, pages 16 - 24, XP029290486 DOI: http://dx.doi.org/10.1016/j.jprot.2015.07.001
	- YANG, C.LI, Z.BHATT, T.DICKLER, M.GIRI, D.SCALTRITI, M.BASELGA, J.ROSEN, N.CHANDARLAPATY, S., "Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence.", Oncogene, (20170000), vol. 36, pages 2255 - 2264
	- YANG, H.W.CHUNG, M.KUDO, T.MEYER, T., "Competing memories of mitogen and p53 signalling control cell-cycle entry.", Nature, (20170000), vol. 549, pages 404 - 408
	- YANG, K.HITOMI, M.STACEY, D.W., "Variations in cyclin D1 levels through the cell cycle determine the proliferative fate of a cell.", Cell Div, (20060000), vol. 1, doi:10.1186/1747-1028-1-32, XP021025973 DOI: http://dx.doi.org/10.1186/1747-1028-1-32
	- ZERJATKE, T.GAK, I.A.KIROVA, D.FUHRMANN, M.DANIEL, K.GONCIARZ, M.MULLER, D.GLAUCHE, I.MANSFELD, J., "Quantitative Cell Cycle Analysis Based on an Endogenous All-in-One Reporter for Cell Tracking and Classification.", Cell Reports, (20170000), vol. 19, pages 1953 - 1966
	- ZHAO, J.KENNEDY, B.K.LAWRENCE, B.D.BARBIE, D.A.MATERA, A.G.FLETCHER, J.A.HARLOW, E., "NPAT links cyclin E-Cdk2 to the regulation of replication-dependent histone gene transcription.", Genes Dev, (20000000), vol. 14, pages 2283 - 2297

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 35p